...Trabectedin is the only approved drug for the treatment of relapsed STS, and it is recommended by the European guidelines for the treatment of advanced or metastatic STS with particular efficacy against leiomyosarcoma and liposarcoma. In phase II clinical trials, trabectedin provided disease control and/or clinical benefit in more than 50% of patients and was accompanied by a median overall survival (OS) rate of up to 14 months. The combination of trabectedin and doxorubicin extends the OS rate to 15 months. These encouraging results support the role of trabectedin in the treatment of STS. The results of ongoing clinical trials investigating the activity of trabectedin in combination with other chemotherapeutic agents and in specific histological subtypes of STS should further define the place of this emerging agent in the management of this difficult‐to‐treat population.
.